Tyme Technologies (NASDAQ:TYME) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Friday, Zacks.com reports. The firm currently has a $1.00 price objective on the stock. Zacks Investment Research‘s price objective would suggest a potential upside of 1.01% from the stock’s previous close.
According to Zacks, “Tyme Technologies, Inc. is a pharmaceutical company. The company is focused on creating medicines which specialize in the body’s immune system to treat diseases. Tyme Technologies, Inc. is headquartered in New York. “
Separately, HC Wainwright assumed coverage on Tyme Technologies in a research report on Monday. They issued a “buy” rating for the company.
TYME traded down $0.01 on Friday, hitting $0.99. The company had a trading volume of 1,224 shares, compared to its average volume of 472,431. The company has a market cap of $113.07 million, a PE ratio of -3.09 and a beta of 0.40. Tyme Technologies has a 12-month low of $0.92 and a 12-month high of $4.64. The business’s fifty day simple moving average is $1.18 and its 200 day simple moving average is $1.68.
Tyme Technologies (NASDAQ:TYME) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.04) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.06) by $0.02. On average, sell-side analysts anticipate that Tyme Technologies will post -0.22 EPS for the current year.
In other Tyme Technologies news, Director David Carberry bought 30,000 shares of the company’s stock in a transaction on Friday, June 14th. The stock was acquired at an average price of $1.07 per share, for a total transaction of $32,100.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Michael Demurjian sold 50,000 shares of the business’s stock in a transaction that occurred on Monday, July 29th. The shares were sold at an average price of $1.11, for a total value of $55,500.00. The disclosure for this sale can be found here. In the last quarter, insiders purchased 60,000 shares of company stock valued at $63,450 and sold 140,000 shares valued at $156,900. Company insiders own 27.17% of the company’s stock.
A number of large investors have recently modified their holdings of the stock. Bank of New York Mellon Corp boosted its stake in Tyme Technologies by 242.9% during the 4th quarter. Bank of New York Mellon Corp now owns 289,819 shares of the company’s stock valued at $1,070,000 after purchasing an additional 205,300 shares during the last quarter. Northern Trust Corp boosted its stake in Tyme Technologies by 26.5% during the 4th quarter. Northern Trust Corp now owns 485,786 shares of the company’s stock valued at $1,793,000 after purchasing an additional 101,734 shares during the last quarter. Geode Capital Management LLC boosted its stake in Tyme Technologies by 263.0% during the 4th quarter. Geode Capital Management LLC now owns 689,612 shares of the company’s stock valued at $2,544,000 after purchasing an additional 499,627 shares during the last quarter. Bank of America Corp DE boosted its stake in Tyme Technologies by 1,066.6% during the 4th quarter. Bank of America Corp DE now owns 42,849 shares of the company’s stock valued at $158,000 after purchasing an additional 39,176 shares during the last quarter. Finally, MetLife Investment Advisors LLC purchased a new stake in Tyme Technologies during the 4th quarter valued at $190,000. 19.58% of the stock is owned by institutional investors.
About Tyme Technologies
Tyme Technologies, Inc, a clinical-stage biotechnology company, develops novel cancer therapeutics. It is developing SM-88, a combination therapy based on dysfunctional metyrosine derivatives in Phase II development for metastatic pancreatic cancer and biomarker-recurrent prostate cancer. The company was founded in 2011 and is headquartered in New York, New York.
See Also: What are convertible shares?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tyme Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyme Technologies and related companies with MarketBeat.com's FREE daily email newsletter.